A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer’s Disease in Taiwan

Chiung-Chih ChangGiia-Sheun PengTe-Jen LaiChien-Hsun LiChing-Kuan Liu2026-01-292026-01-292019-04-0510.1007/s12325-019-00939-0https://scholars.csmu.edu.tw/handle/123456789/3826[SDGs]SDG3A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer’s Disease in Taiwanjournal-article